25 XP   0   0   10

Kura Oncology Inc
Buy, Hold or Sell?

Let's analyse Kura Oncology Inc together

PenkeI guess you are interested in Kura Oncology Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Kura Oncology Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Kura Oncology Inc

I send you an email if I find something interesting about Kura Oncology Inc.

Quick analysis of Kura Oncology Inc (30 sec.)










What can you expect buying and holding a share of Kura Oncology Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$5.14
Expected worth in 1 year
$4.75
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$-0.38
Return On Investment
-2.2%

For what price can you sell your share?

Current Price per Share
$17.68
Expected price per share
$16.37 - $24.17
How sure are you?
50%

1. Valuation of Kura Oncology Inc (5 min.)




Live pricePrice per Share (EOD)

$17.68

Intrinsic Value Per Share

$-20.52 - $-14.13

Total Value Per Share

$-15.38 - $-8.99

2. Growth of Kura Oncology Inc (5 min.)




Is Kura Oncology Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$397.2m$441.4m-$14.9m-3.5%

How much money is Kura Oncology Inc making?

Current yearPrevious yearGrowGrow %
Making money-$37.3m-$34.5m-$2.8m-7.7%
Net Profit Margin-842.2%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Kura Oncology Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#138 / 1016

Most Revenue
#578 / 1016

Most Profit
#844 / 1016

Most Efficient
#793 / 1016

What can you expect buying and holding a share of Kura Oncology Inc? (5 min.)

Welcome investor! Kura Oncology Inc's management wants to use your money to grow the business. In return you get a share of Kura Oncology Inc.

What can you expect buying and holding a share of Kura Oncology Inc?

First you should know what it really means to hold a share of Kura Oncology Inc. And how you can make/lose money.

Speculation

The Price per Share of Kura Oncology Inc is $17.68. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Kura Oncology Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Kura Oncology Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.14. Based on the TTM, the Book Value Change Per Share is $-0.10 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.28 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Kura Oncology Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.55-3.1%-0.50-2.8%-0.45-2.5%-0.37-2.1%-0.25-1.4%
Usd Book Value Change Per Share-0.43-2.4%-0.10-0.5%-0.28-1.6%0.150.9%0.130.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.43-2.4%-0.10-0.5%-0.28-1.6%0.150.9%0.130.7%
Usd Price Per Share14.38-11.58-15.12-17.17-12.19-
Price to Earnings Ratio-6.50--5.83--8.48--12.93--12.02-
Price-to-Total Gains Ratio-33.50--18.28-327.71-28.25--2.78-
Price to Book Ratio2.80-2.11-2.60-3.68-4.97-
Price-to-Total Gains Ratio-33.50--18.28-327.71-28.25--2.78-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share17.68
Number of shares56
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.100.15
Usd Total Gains Per Share-0.100.15
Gains per Quarter (56 shares)-5.368.46
Gains per Year (56 shares)-21.4533.85
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-21-3103424
20-43-5206858
30-64-73010292
40-86-940135126
50-107-1150169160
60-129-1360203194
70-150-1570237228
80-172-1780271262
90-193-1990305296
100-215-2200339330

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.053.00.00.0%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%5.015.00.025.0%10.030.00.025.0%10.043.00.018.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.053.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%5.015.00.025.0%10.030.00.025.0%10.043.00.018.9%

Fundamentals of Kura Oncology Inc

About Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Fundamental data was last updated by Penke on 2024-04-11 12:55:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Kura Oncology Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Kura Oncology Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Kura Oncology Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -3,369.0% means that $-33.69 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Kura Oncology Inc:

  • The MRQ is -3,369.0%. The company is making a huge loss. -2
  • The TTM is -842.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-3,369.0%TTM-842.2%-2,526.7%
TTM-842.2%YOY--842.2%
TTM-842.2%5Y-168.4%-673.8%
5Y-168.4%10Y-100.7%-67.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3,369.0%-199.6%-3,169.4%
TTM-842.2%-213.0%-629.2%
YOY--279.3%+279.3%
5Y-168.4%-438.4%+270.0%
10Y-100.7%-605.5%+504.8%
1.1.2. Return on Assets

Shows how efficient Kura Oncology Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Kura Oncology Inc to the Biotechnology industry mean.
  • -9.5% Return on Assets means that Kura Oncology Inc generated $-0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Kura Oncology Inc:

  • The MRQ is -9.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -8.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.5%TTM-8.1%-1.4%
TTM-8.1%YOY-7.4%-0.7%
TTM-8.1%5Y-6.9%-1.2%
5Y-6.9%10Y-18.3%+11.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.5%-13.5%+4.0%
TTM-8.1%-12.9%+4.8%
YOY-7.4%-11.8%+4.4%
5Y-6.9%-14.1%+7.2%
10Y-18.3%-16.0%-2.3%
1.1.3. Return on Equity

Shows how efficient Kura Oncology Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Kura Oncology Inc to the Biotechnology industry mean.
  • -10.8% Return on Equity means Kura Oncology Inc generated $-0.11 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Kura Oncology Inc:

  • The MRQ is -10.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -4.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.8%TTM-4.9%-5.8%
TTM-4.9%YOY-5.9%+0.9%
TTM-4.9%5Y-6.3%+1.3%
5Y-6.3%10Y-7.8%+1.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.8%-16.9%+6.1%
TTM-4.9%-16.1%+11.2%
YOY-5.9%-15.1%+9.2%
5Y-6.3%-19.9%+13.6%
10Y-7.8%-20.9%+13.1%

1.2. Operating Efficiency of Kura Oncology Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Kura Oncology Inc is operating .

  • Measures how much profit Kura Oncology Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Kura Oncology Inc to the Biotechnology industry mean.
  • An Operating Margin of -3,682.0% means the company generated $-36.82  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Kura Oncology Inc:

  • The MRQ is -3,682.0%. The company is operating very inefficient. -2
  • The TTM is -920.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-3,682.0%TTM-920.5%-2,761.5%
TTM-920.5%YOY--920.5%
TTM-920.5%5Y-184.1%-736.4%
5Y-184.1%10Y-109.1%-75.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3,682.0%-295.1%-3,386.9%
TTM-920.5%-225.8%-694.7%
YOY--288.4%+288.4%
5Y-184.1%-477.4%+293.3%
10Y-109.1%-625.6%+516.5%
1.2.2. Operating Ratio

Measures how efficient Kura Oncology Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 36.82 means that the operating costs are $36.82 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Kura Oncology Inc:

  • The MRQ is 36.820. The company is inefficient in keeping operating costs low. -1
  • The TTM is 9.205. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ36.820TTM9.205+27.615
TTM9.205YOY-+9.205
TTM9.2055Y1.841+7.364
5Y1.84110Y1.091+0.750
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ36.8203.090+33.730
TTM9.2053.264+5.941
YOY-3.783-3.783
5Y1.8415.679-3.838
10Y1.0917.894-6.803

1.3. Liquidity of Kura Oncology Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Kura Oncology Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 12.26 means the company has $12.26 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Kura Oncology Inc:

  • The MRQ is 12.264. The company is very able to pay all its short-term debts. +2
  • The TTM is 17.646. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ12.264TTM17.646-5.382
TTM17.646YOY22.349-4.703
TTM17.6465Y20.239-2.593
5Y20.23910Y15.437+4.802
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.2643.914+8.350
TTM17.6464.220+13.426
YOY22.3495.388+16.961
5Y20.2396.045+14.194
10Y15.4376.406+9.031
1.3.2. Quick Ratio

Measures if Kura Oncology Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Kura Oncology Inc to the Biotechnology industry mean.
  • A Quick Ratio of 23.07 means the company can pay off $23.07 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Kura Oncology Inc:

  • The MRQ is 23.067. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 33.431. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ23.067TTM33.431-10.365
TTM33.431YOY41.411-7.980
TTM33.4315Y36.399-2.967
5Y36.39910Y27.507+8.892
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ23.0673.572+19.495
TTM33.4313.998+29.433
YOY41.4115.390+36.021
5Y36.3995.969+30.430
10Y27.5076.287+21.220

1.4. Solvency of Kura Oncology Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Kura Oncology Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Kura Oncology Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.12 means that Kura Oncology Inc assets are financed with 11.5% credit (debt) and the remaining percentage (100% - 11.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Kura Oncology Inc:

  • The MRQ is 0.115. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.076. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.115TTM0.076+0.039
TTM0.076YOY0.058+0.017
TTM0.0765Y0.072+0.003
5Y0.07210Y2.245-2.173
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1150.336-0.221
TTM0.0760.334-0.258
YOY0.0580.269-0.211
5Y0.0720.366-0.294
10Y2.2450.390+1.855
1.4.2. Debt to Equity Ratio

Measures if Kura Oncology Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Kura Oncology Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 13.0% means that company has $0.13 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Kura Oncology Inc:

  • The MRQ is 0.130. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.058. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.130TTM0.058+0.072
TTM0.058YOY0.041+0.017
TTM0.0585Y0.070-0.012
5Y0.07010Y0.096-0.026
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1300.382-0.252
TTM0.0580.396-0.338
YOY0.0410.335-0.294
5Y0.0700.434-0.364
10Y0.0960.465-0.369

2. Market Valuation of Kura Oncology Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Kura Oncology Inc generates.

  • Above 15 is considered overpriced but always compare Kura Oncology Inc to the Biotechnology industry mean.
  • A PE ratio of -6.50 means the investor is paying $-6.50 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Kura Oncology Inc:

  • The EOD is -7.989. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.498. Based on the earnings, the company is expensive. -2
  • The TTM is -5.828. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.989MRQ-6.498-1.491
MRQ-6.498TTM-5.828-0.670
TTM-5.828YOY-8.481+2.653
TTM-5.8285Y-12.934+7.106
5Y-12.93410Y-12.016-0.918
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.989-2.259-5.730
MRQ-6.498-2.569-3.929
TTM-5.828-2.664-3.164
YOY-8.481-4.120-4.361
5Y-12.934-6.258-6.676
10Y-12.016-6.171-5.845
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Kura Oncology Inc:

  • The EOD is -9.959. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -8.100. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -7.119. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.959MRQ-8.100-1.859
MRQ-8.100TTM-7.119-0.981
TTM-7.119YOY-10.495+3.376
TTM-7.1195Y-15.767+8.648
5Y-15.76710Y-16.042+0.275
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-9.959-2.924-7.035
MRQ-8.100-3.246-4.854
TTM-7.119-3.488-3.631
YOY-10.495-5.620-4.875
5Y-15.767-8.315-7.452
10Y-16.042-8.826-7.216
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Kura Oncology Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.80 means the investor is paying $2.80 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Kura Oncology Inc:

  • The EOD is 3.442. Based on the equity, the company is fair priced.
  • The MRQ is 2.799. Based on the equity, the company is underpriced. +1
  • The TTM is 2.115. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.442MRQ2.799+0.642
MRQ2.799TTM2.115+0.684
TTM2.115YOY2.601-0.486
TTM2.1155Y3.683-1.568
5Y3.68310Y4.969-1.286
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.4421.851+1.591
MRQ2.7992.090+0.709
TTM2.1152.095+0.020
YOY2.6012.844-0.243
5Y3.6833.466+0.217
10Y4.9693.815+1.154
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Kura Oncology Inc.

3.1. Institutions holding Kura Oncology Inc

Institutions are holding 105.538% of the shares of Kura Oncology Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc9.60850.002773156473946025.7015
2023-12-31Suvretta Capital Management, LLC9.12334.5166946230-389615-5.3111
2023-09-30Bvf Inc8.84061.6553673098300
2023-12-31EcoR1 Capital, LLC7.62692.168580687100
2023-09-30Deerfield Management Co5.7450.87894374044113604435.0847
2023-12-31Vanguard Group Inc5.30320.001340376911132432.8856
2023-12-31venBio Select Advisor LLC3.9140.5919298000000
2023-12-31State Street Corporation3.83760.0022921810-334777-10.28
2023-09-30Holocene Advisors, LP3.20140.0973243746300
2023-12-31Armistice Capital, LLC2.92110.43662224000-12000-0.5367
2023-12-31Dimensional Fund Advisors, Inc.2.62910.0084200175419753010.9482
2023-12-31Foresite Capital Management IV, LLC2.429813.4441184994700
2023-12-31Artal Group S A2.32220.84521768056-250000-12.3882
2023-12-31Sofinnova Ventures2.18991.3416166732116673210
2023-12-31Geode Capital Management, LLC2.1750.00251656009780534.9465
2023-09-30Citadel Advisors Llc1.93370.00291472292-444323-23.1827
2023-12-31TCG Crossover Management, LLC1.86982.2704142364200
2023-12-31Franklin Resources Inc1.77790.0091135366513071010.688
2023-12-31Morgan Stanley - Brokerage Accounts1.74810.001713309551169992726.8702
2023-12-31Paradigm Biocapital Advisors LP1.65860.85021262828500004.1226
Total 80.855729.126161561208+3506780+5.7%

3.2. Funds holding Kura Oncology Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-28SPDR® S&P Biotech ETF3.40630.73262593417327201.2778
2024-02-29Vanguard Total Stock Mkt Idx Inv2.89950.003220756400
2024-03-28iShares Russell 2000 ETF2.26550.056217248598310.0482
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.47750.02321124924-26356-2.2893
2024-01-31Fidelity Small Cap Index0.93660.0579713094107181.526
2024-02-29Franklin Small Cap Growth Adv0.90110.498768610000
2024-03-28iShares Russell 2000 Value ETF0.8710.1128663115-420-0.0633
2023-12-31Franklin US Small Cap Growth Equity0.75090.296657170000
2024-02-29Franklin Biotechnology Discv A(acc)USD0.70120.609853390200
2024-03-28iShares Biotechnology ETF0.63550.1353483878-3616-0.7418
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.56270.021642839477001.8303
2024-02-29Fidelity Extended Market Index0.55460.023242225174801.8034
2024-02-29Belfius Equities Cure C Cap0.5280.448640199600
2023-12-31Candriam Global Equities Oncology0.4820.2842366996-100000-21.4135
2024-03-29Schwab US Small-Cap ETF™0.47040.044735815300
2024-02-29BlackRock Advantage Small Cap Core Instl0.4580.2094348713-29182-7.7223
2024-03-31Direxion Daily S&P Biotech Bull 3X ETF0.40880.5316311268-2184-0.6968
2024-02-29Franklin Biotechnology Discovery A0.35160.586726768200
2024-02-29DFA US Micro Cap I0.34140.0764259923112294.5152
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.34110.056825971300
Total 19.34374.809314727642-91080-0.6%

3.3. Insider Transactions

Insiders are holding 1.75% of the shares of Kura Oncology Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-01-29Kathleen FordSELL149617.8
2024-01-29Teresa Brophy BairSELL205317.8
2024-01-29Thomas James DoyleSELL231817.8
2024-01-24Troy Edward WilsonSELL9105220.23
2023-06-16Thomas MalleyBUY5000011.5

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Kura Oncology Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.429-0.096-78%-0.283-34%0.151-384%0.128-434%
Book Value Per Share--5.1375.561-8%5.798-11%5.211-1%3.037+69%
Current Ratio--12.26417.646-30%22.349-45%20.239-39%15.437-21%
Debt To Asset Ratio--0.1150.076+52%0.058+97%0.072+59%2.245-95%
Debt To Equity Ratio--0.1300.058+124%0.041+219%0.070+87%0.096+35%
Dividend Per Share----0%-0%-0%-0%
Eps---0.553-0.497-10%-0.446-19%-0.375-32%-0.250-55%
Free Cash Flow Per Share---0.444-0.407-8%-0.363-18%-0.307-31%-0.193-57%
Free Cash Flow To Equity Per Share---0.4350.213-305%-0.237-46%0.221-296%0.190-329%
Gross Profit Margin--1.0051.001+0%1.000+1%1.000+0%1.000+0%
Intrinsic Value_10Y_max---14.128--------
Intrinsic Value_10Y_min---20.516--------
Intrinsic Value_1Y_max---0.866--------
Intrinsic Value_1Y_min---1.597--------
Intrinsic Value_3Y_max---3.021--------
Intrinsic Value_3Y_min---5.223--------
Intrinsic Value_5Y_max---5.682--------
Intrinsic Value_5Y_min---9.290--------
Market Cap1346102160.000+17%1112106060.000888307237.500+25%1151191440.000-3%1308600445.500-15%928678936.500+20%
Net Profit Margin---33.690-8.422-75%--100%-1.684-95%-1.007-97%
Operating Margin---36.820-9.205-75%--100%-1.841-95%-1.091-97%
Operating Ratio--36.8209.205+300%-+100%1.841+1900%1.091+3274%
Pb Ratio3.442+19%2.7992.115+32%2.601+8%3.683-24%4.969-44%
Pe Ratio-7.989-23%-6.498-5.828-10%-8.481+31%-12.934+99%-12.016+85%
Price Per Share17.680+19%14.38011.578+24%15.120-5%17.170-16%12.189+18%
Price To Free Cash Flow Ratio-9.959-23%-8.100-7.119-12%-10.495+30%-15.767+95%-16.042+98%
Price To Total Gains Ratio-41.186-23%-33.499-18.276-45%327.711-110%28.251-219%-2.779-92%
Quick Ratio--23.06733.431-31%41.411-44%36.399-37%27.507-16%
Return On Assets---0.095-0.081-15%-0.074-22%-0.069-28%-0.183+92%
Return On Equity---0.108-0.049-54%-0.059-46%-0.063-42%-0.078-27%
Total Gains Per Share---0.429-0.096-78%-0.283-34%0.151-384%0.128-434%
Usd Book Value--397273000.000426492500.000-7%441410000.000-10%397399950.0000%231547548.450+72%
Usd Book Value Change Per Share---0.429-0.096-78%-0.283-34%0.151-384%0.128-434%
Usd Book Value Per Share--5.1375.561-8%5.798-11%5.211-1%3.037+69%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.553-0.497-10%-0.446-19%-0.375-32%-0.250-55%
Usd Free Cash Flow---34324000.000-31248000.000-9%-27672000.000-19%-23406950.000-32%-14714905.850-57%
Usd Free Cash Flow Per Share---0.444-0.407-8%-0.363-18%-0.307-31%-0.193-57%
Usd Free Cash Flow To Equity Per Share---0.4350.213-305%-0.237-46%0.221-296%0.190-329%
Usd Market Cap1346102160.000+17%1112106060.000888307237.500+25%1151191440.000-3%1308600445.500-15%928678936.500+20%
Usd Price Per Share17.680+19%14.38011.578+24%15.120-5%17.170-16%12.189+18%
Usd Profit---42786000.000-37391000.000-13%-34513000.000-19%-28542350.000-33%-17923540.275-58%
Usd Revenue--1270000.000317500.000+300%-+100%63500.000+1900%92650.000+1271%
Usd Total Gains Per Share---0.429-0.096-78%-0.283-34%0.151-384%0.128-434%
 EOD+5 -3MRQTTM+7 -27YOY+3 -315Y+4 -3010Y+11 -23

4.2. Fundamental Score

Let's check the fundamental score of Kura Oncology Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-7.989
Price to Book Ratio (EOD)Between0-13.442
Net Profit Margin (MRQ)Greater than0-33.690
Operating Margin (MRQ)Greater than0-36.820
Quick Ratio (MRQ)Greater than123.067
Current Ratio (MRQ)Greater than112.264
Debt to Asset Ratio (MRQ)Less than10.115
Debt to Equity Ratio (MRQ)Less than10.130
Return on Equity (MRQ)Greater than0.15-0.108
Return on Assets (MRQ)Greater than0.05-0.095
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Kura Oncology Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.188
Ma 20Greater thanMa 5020.211
Ma 50Greater thanMa 10020.801
Ma 100Greater thanMa 20017.539
OpenGreater thanClose17.860
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Gross Profit  -2060-206-7-213-3-2161,2721,056



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets448,935
Total Liabilities51,662
Total Stockholder Equity397,273
 As reported
Total Liabilities 51,662
Total Stockholder Equity+ 397,273
Total Assets = 448,935

Assets

Total Assets448,935
Total Current Assets432,481
Long-term Assets16,454
Total Current Assets
Cash And Cash Equivalents 37,318
Short-term Investments 386,639
Net Receivables 2,800
Other Current Assets 5,724
Total Current Assets  (as reported)432,481
Total Current Assets  (calculated)432,481
+/-0
Long-term Assets
Property Plant Equipment 8,852
Long-term Assets Other 7,402
Long-term Assets  (as reported)16,454
Long-term Assets  (calculated)16,254
+/- 200

Liabilities & Shareholders' Equity

Total Current Liabilities35,263
Long-term Liabilities16,399
Total Stockholder Equity397,273
Total Current Liabilities
Short-term Debt 1,506
Accounts payable 2,300
Other Current Liabilities 31,457
Total Current Liabilities  (as reported)35,263
Total Current Liabilities  (calculated)35,263
+/-0
Long-term Liabilities
Long term Debt 9,332
Capital Lease Obligations Min Short Term Debt6,362
Long-term Liabilities Other 705
Long-term Liabilities  (as reported)16,399
Long-term Liabilities  (calculated)16,399
+/-0
Total Stockholder Equity
Common Stock7
Retained Earnings -721,439
Accumulated Other Comprehensive Income -1,271
Other Stockholders Equity 1,119,976
Total Stockholder Equity (as reported)397,273
Total Stockholder Equity (calculated)397,273
+/-0
Other
Capital Stock7
Cash and Short Term Investments 423,957
Common Stock Shares Outstanding 77,337
Liabilities and Stockholders Equity 448,935
Net Debt -20,118
Net Invested Capital 406,605
Net Working Capital 397,218
Property Plant and Equipment Gross 11,304
Short Long Term Debt Total 17,200



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-31
> Total Assets 
28
17
12
8
7
21
16
11
11
6
29
25
16
11
7
24
16
11
8
4
19
15
9
7
5
18
6
54,800
47,500
42,827
87,259
80,382
81,744
76,304
69,821
61,919
55,847
103,115
95,851
141,458
129,627
191,500
182,379
169,617
265,685
254,602
241,972
226,462
353,000
339,567
647,212
620,263
584,891
561,141
534,051
498,585
471,425
447,988
456,306
425,975
494,737
473,771
448,935
448,935473,771494,737425,975456,306447,988471,425498,585534,051561,141584,891620,263647,212339,567353,000226,462241,972254,602265,685169,617182,379191,500129,627141,45895,851103,11555,84761,91969,82176,30481,74480,38287,25942,82747,50054,80061857915194811162471116252961111162178121728
   > Total Current Assets 
28
12
9
8
7
17
13
11
6
2
27
25
16
11
7
24
16
11
8
4
19
11
7
6
5
18
6
54,600
47,200
42,306
86,869
80,075
81,421
75,715
68,810
60,628
54,735
101,923
94,641
140,361
128,535
190,392
181,197
167,586
263,904
252,948
239,603
221,130
342,186
328,911
637,292
610,705
573,632
548,905
522,289
487,034
459,786
436,391
446,426
416,450
476,979
459,917
432,481
432,481459,917476,979416,450446,426436,391459,786487,034522,289548,905573,632610,705637,292328,911342,186221,130239,603252,948263,904167,586181,197190,392128,535140,36194,641101,92354,73560,62868,81075,71581,42180,07586,86942,30647,20054,600618567111948111624711162527261113177891228
       Cash And Cash Equivalents 
28
12
9
8
7
17
13
11
6
2
27
25
9
6
4
24
9
6
5
3
19
11
7
6
5
18
6
53,600
19,800
11,215
15,443
16,326
12,112
6,783
9,725
10,642
12,154
23,336
11,433
26,518
17,658
20,568
16,119
17,778
122,080
54,742
26,135
33,811
134,758
76,955
325,493
110,835
38,974
39,183
90,672
33,832
39,257
90,937
51,802
27,059
49,124
28,740
37,318
37,31828,74049,12427,05951,80290,93739,25733,83290,67239,18338,974110,835325,49376,955134,75833,81126,13554,742122,08017,77816,11920,56817,65826,51811,43323,33612,15410,6429,7256,78312,11216,32615,44311,21519,80053,60061856711193569244692527261113177891228
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
26,100
30,017
70,303
62,140
67,978
67,785
58,065
48,511
41,090
77,469
81,712
111,682
108,227
166,855
162,866
147,747
139,333
195,384
210,756
183,124
204,111
248,458
307,827
493,038
528,520
504,262
427,288
446,243
411,001
336,838
386,183
378,841
427,855
423,853
386,639
386,639423,853427,855378,841386,183336,838411,001446,243427,288504,262528,520493,038307,827248,458204,111183,124210,756195,384139,333147,747162,866166,855108,227111,68281,71277,46941,09048,51158,06567,78567,97862,14070,30330,01726,1000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
300
400
379
430
406
286
261
295
341
304
209
216
257
230
232
224
179
111
47
30
31
0
0
0
0
0
0
0
0
0
0
900
0
3,700
0
2,800
2,80003,70009000000000000313047111179224232230257216209304341295261286406430379400300000000000000000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
6
4
3
1
6
6
4
1
0
4
3
1
0
0
0
700
900
695
693
1,203
1,045
886
725
1,134
1,187
909
1,280
1,904
2,420
2,737
1,988
1,882
2,380
2,775
2,682
4,164
3,317
3,498
3,972
6,832
6,138
5,460
4,329
6,959
9,528
8,616
8,441
10,550
8,667
7,324
5,724
5,7247,3248,66710,5508,4418,6169,5286,9594,3295,4606,1386,8323,9723,4983,3174,1642,6822,7752,3801,8821,9882,7372,4201,9041,2809091,1871,1347258861,0451,203693695900700000134014661346000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
3
0
0
0
3
0
0
0
4
0
0
4
3
1
0
0
0
200
300
521
390
307
323
589
1,011
1,291
1,112
1,192
1,210
1,097
1,092
1,108
1,182
2,031
1,781
1,654
2,369
5,332
10,814
10,656
9,920
9,558
11,259
12,236
11,762
11,551
11,639
11,597
9,880
9,525
9,091
13,854
16,454
16,45413,8549,0919,5259,88011,59711,63911,55111,76212,23611,2599,5589,92010,65610,8145,3322,3691,6541,7812,0311,1821,1081,0921,0971,2101,1921,1121,2911,011589323307390521300200000134004000300030000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
34
100
78
71
62
55
47
40
32
24
17
10
5
1
0
0
588
477
357
44
805
8,760
8,814
8,355
8,018
7,743
8,720
8,246
7,716
7,265
7,018
6,382
5,761
5,186
9,338
8,852
8,8529,3385,1865,7616,3827,0187,2657,7168,2468,7207,7438,0188,3558,8148,7608054435747758800151017243240475562717810034000000000000000000000000000
       Other Assets 
0
5
3
0
0
5
3
0
6
4
0
1
6
4
-3
1
6
6
-4
1
0
0
0
0
0
0
0
155
284
443
319
245
268
542
971
1,259
1,088
1,175
1,200
1,092
1,091
1,108
1,182
1,443
1,304
1,297
2,091
2,327
2,054
1,842
7,899
1,540
3,516
3,516
3,516
3,835
4,374
4,579
3,498
0
8,667
0
0
008,66703,4984,5794,3743,8353,5163,5163,5161,5407,8991,8422,0542,3272,0911,2971,3041,4431,1821,1081,0911,0921,2001,1751,0881,25997154226824531944328415500000001-4661-346104603500350
> Total Liabilities 
0
0
0
0
0
27
27
34
40
39
70
71
68
70
75
98
95
97
104
105
127
129
133
137
142
161
160
5,900
4,200
5,043
5,156
4,316
11,703
12,638
12,945
11,678
12,210
13,916
15,986
16,658
17,230
16,893
21,394
20,052
19,104
21,018
23,191
23,261
30,626
33,072
36,307
34,276
26,340
27,385
27,442
22,335
21,934
28,367
36,028
30,792
11,160
43,834
51,662
51,66243,83411,16030,79236,02828,36721,93422,33527,44227,38526,34034,27636,30733,07230,62623,26123,19121,01819,10420,05221,39416,89317,23016,65815,98613,91612,21011,67812,94512,63811,7034,3165,1565,0434,2005,9001601611421371331291271051049795987570687170394034272700000
   > Total Current Liabilities 
0
0
0
0
0
25
25
25
35
35
60
60
68
70
75
98
95
97
104
105
110
111
110
111
118
136
127
5,500
3,600
4,711
5,055
4,310
4,384
5,272
5,451
4,116
5,076
7,562
10,031
11,351
12,580
12,905
13,615
12,143
11,232
13,112
15,564
14,554
18,551
21,705
26,024
25,139
21,290
21,926
22,455
17,725
17,873
24,745
24,057
19,233
23,899
27,525
35,263
35,26327,52523,89919,23324,05724,74517,87317,72522,45521,92621,29025,13926,02421,70518,55114,55415,56413,11211,23212,14313,61512,90512,58011,35110,0317,5625,0764,1165,4515,2724,3844,3105,0554,7113,6005,5001271361181111101111101051049795987570686060353525252500000
       Short-term Debt 
0
0
0
0
0
25
25
25
35
35
60
60
60
60
60
85
85
85
85
85
110
110
110
110
110
125
125
0
0
0
0
0
0
0
7,324
0
500
1,024
1,531
2,294
2,813
2,834
0
484
0
0
250
1,000
3,495
4,403
5,089
5,102
1,981
2,250
2,263
2,276
2,290
2,304
2,318
2,332
2,345
1,682
1,506
1,5061,6822,3452,3322,3182,3042,2902,2762,2632,2501,9815,1025,0894,4033,4951,0002500048402,8342,8132,2941,5311,02450007,324000000012512511011011011011085858585856060606060353525252500000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,324
0
7,355
1,024
1,531
2,294
2,813
2,834
0
484
0
0
250
1,000
1,750
2,500
3,000
3,000
0
0
0
0
0
0
0
0
0
0
0
000000000003,0003,0002,5001,7501,0002500048402,8342,8132,2941,5311,0247,35507,3240000000000000000000000000000000000
       Accounts payable 
0
0
0
0
0
0
0
0
0
0
0
0
2
2
3
4
0
1
2
6
0
1
0
1
8
11
2
3,600
700
1,464
1,839
1,974
1,253
1,905
1,408
1,026
1,015
1,003
1,464
2,430
2,192
2,092
4,120
3,435
3,910
2,991
3,526
2,453
786
814
2,753
958
2,404
2,875
3,236
1,337
1,395
1,746
1,533
3,291
2,337
1,762
2,300
2,3001,7622,3373,2911,5331,7461,3951,3373,2362,8752,4049582,7538147862,4533,5262,9913,9103,4354,1202,0922,1922,4301,4641,0031,0151,0261,4081,9051,2531,9741,8391,4647003,6002118101062104322000000000000
       Other Current Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
6
7
12
9
10
12
17
14
0
0
0
0
0
0
0
1,900
2,900
3,247
3,216
2,336
3,131
3,367
4,043
3,090
3,561
5,535
7,036
6,627
7,575
7,979
9,495
8,708
7,322
10,121
11,788
11,101
14,270
16,488
18,182
19,079
16,905
16,801
16,956
14,112
14,188
20,695
20,206
13,610
21,554
25,843
31,457
31,45725,84321,55413,61020,20620,69514,18814,11216,95616,80116,90519,07918,18216,48814,27011,10111,78810,1217,3228,7089,4957,9797,5756,6277,0365,5353,5613,0904,0433,3673,1312,3363,2163,2472,9001,90000000001417121091276000000000000
   > Long-term Liabilities 
0
0
0
0
0
2
2
9
5
4
10
11
60
60
60
85
85
85
85
85
110
110
110
110
110
125
125
400
600
332
101
6
7,319
7,366
7,494
7,562
7,134
6,354
5,955
5,307
4,650
3,988
7,779
7,909
7,872
7,906
7,627
8,707
12,075
11,367
10,283
9,137
5,050
5,459
4,987
4,610
4,061
3,622
11,971
11,559
11,160
16,309
16,399
16,39916,30911,16011,55911,9713,6224,0614,6104,9875,4595,0509,13710,28311,36712,0758,7077,6277,9067,8727,9097,7793,9884,6505,3075,9556,3547,1347,5627,4947,3667,3196101332600400125125110110110110110858585858560606011104592200000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,292
7,308
7,324
7,339
6,855
6,018
5,567
4,861
4,150
3,432
7,500
7,500
7,500
7,500
7,250
6,500
5,750
5,000
4,250
3,500
0
0
0
0
0
0
9,158
9,200
0
0
0
0009,2009,1580000003,5004,2505,0005,7506,5007,2507,5007,5007,5007,5003,4324,1504,8615,5676,0186,8557,3397,3247,3087,29200000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
391
604
332
101
6
27
58
170
223
279
336
388
446
500
556
279
295
349
406
377
407
306
344
395
441
295
356
375
496
459
542
265
0
461
0
0
00461026554245949637535629544139534430640737740634929527955650044638833627922317058276101332604391000000000000000000000000000
> Total Stockholder Equity
26
15
11
1
-2
-6
-11
-23
-28
-33
-41
-46
-53
-59
-68
-73
-80
-86
-95
-101
-108
-114
-124
-130
-137
-143
-155
48,900
43,300
37,784
82,103
76,066
70,041
63,666
56,876
50,241
43,637
89,199
79,865
124,800
112,397
174,607
160,985
149,565
246,581
233,584
218,781
203,201
322,374
306,495
610,905
585,987
558,551
533,756
506,609
476,250
449,491
419,621
-568,808
-602,877
-640,051
429,937
397,273
397,273429,937-640,051-602,877-568,808419,621449,491476,250506,609533,756558,551585,987610,905306,495322,374203,201218,781233,584246,581149,565160,985174,607112,397124,80079,86589,19943,63750,24156,87663,66670,04176,06682,10337,78443,30048,900-155-143-137-130-124-114-108-101-95-86-80-73-68-59-53-46-41-33-28-23-11-6-21111526
   Common Stock
1
0
1
1
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
3
3
3
3
4
4
4
5
5
5
5
6
6
7
7
7
7
7
7
7
7
7
7
7
7
7
777777777777766555544433332222222111111111111111111111111101101
   Retained Earnings -721,439-678,653-640,051-602,877-568,808-535,694-500,190-465,421-432,968-400,225-366,859-333,196-302,502-276,343-252,574-232,087-212,877-195,012-178,620-163,677-149,737-133,640-118,633-103,894-89,290-78,542-69,209-61,389-53,856-46,509-39,583-32,922-26,296-19,822-13,700-8,100-205-193-187-180-174-164-158-151-145-136-130-123-118-109-103-96-91-83-78-73-61-56-52-49-39-35-24
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
50
50
0
0
0
0
50
50
50
50
50
50
50
50
50
57,040
57,069
57,604
108,484
108,975
109,577
110,162
110,748
111,647
112,866
167,752
169,201
228,759
231,120
308,366
310,849
313,220
425,035
428,259
431,322
434,722
574,385
582,608
913,354
919,258
925,796
934,168
941,359
948,312
957,489
964,724
997,111
1,003,949
0
0
0
0001,003,949997,111964,724957,489948,312941,359934,168925,796919,258913,354582,608574,385434,722431,322428,259425,035313,220310,849308,366231,120228,759169,201167,752112,866111,647110,748110,162109,577108,975108,48457,60457,06957,04050505050505050505000005050000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
56,999
57,000
57,604
108,484
108,975
109,577
110,162
110,748
111,647
112,866
167,752
169,201
228,759
231,120
308,366
310,849
313,220
425,035
428,259
431,322
434,722
574,385
582,608
913,354
919,258
925,796
934,168
941,359
948,312
957,489
964,724
8,025
5,889
5,215
1,112,118
1,119,976
1,119,9761,112,1185,2155,8898,025964,724957,489948,312941,359934,168925,796919,258913,354582,608574,385434,722431,322428,259425,035313,220310,849308,366231,120228,759169,201167,752112,866111,647110,748110,162109,577108,975108,48457,60457,00056,999505050505050505050505050505050505050505050505050505050



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-849
Gross Profit-849-849
 
Operating Income (+$)
Gross Profit-849
Operating Expense-164,955
Operating Income-165,804-165,804
 
Operating Expense (+$)
Research Development115,235
Selling General Administrative50,569
Selling And Marketing Expenses849
Operating Expense164,955166,653
 
Net Interest Income (+$)
Interest Income12,623
Interest Expense-1,549
Other Finance Cost-165
Net Interest Income11,239
 
Pretax Income (+$)
Operating Income-165,804
Net Interest Income11,239
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-152,631-178,977
EBIT - interestExpense = -167,353
-152,631
-151,082
Interest Expense1,549
Earnings Before Interest and Taxes (EBIT)-165,804-151,082
Earnings Before Interest and Taxes (EBITDA)-164,955
 
After tax Income (+$)
Income Before Tax-152,631
Tax Provision-0
Net Income From Continuing Ops-142,959-152,631
Net Income-152,631
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses165,804
Total Other Income/Expenses Net13,173-11,239
 

Technical Analysis of Kura Oncology Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Kura Oncology Inc. The general trend of Kura Oncology Inc is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Kura Oncology Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (28.6%) Bearish trend (-28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Kura Oncology Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 19.18 < 19.26 < 24.17.

The bearish price targets are: 17.49 > 17.27 > 16.37.

Tweet this
Kura Oncology Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Kura Oncology Inc. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Kura Oncology Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Kura Oncology Inc. The current macd is -0.70891806.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Kura Oncology Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Kura Oncology Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Kura Oncology Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Kura Oncology Inc Daily Moving Average Convergence/Divergence (MACD) ChartKura Oncology Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Kura Oncology Inc. The current adx is 20.50.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Kura Oncology Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Kura Oncology Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Kura Oncology Inc. The current sar is 19.52.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Kura Oncology Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Kura Oncology Inc. The current rsi is 31.19. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Kura Oncology Inc Daily Relative Strength Index (RSI) ChartKura Oncology Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Kura Oncology Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Kura Oncology Inc price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Kura Oncology Inc Daily Stochastic Oscillator ChartKura Oncology Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Kura Oncology Inc. The current cci is -199.4861619.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Kura Oncology Inc Daily Commodity Channel Index (CCI) ChartKura Oncology Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Kura Oncology Inc. The current cmo is -54.21672709.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Kura Oncology Inc Daily Chande Momentum Oscillator (CMO) ChartKura Oncology Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Kura Oncology Inc. The current willr is -96.33867277.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Kura Oncology Inc Daily Williams %R ChartKura Oncology Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Kura Oncology Inc.

Kura Oncology Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Kura Oncology Inc. The current atr is 0.99044443.

Kura Oncology Inc Daily Average True Range (ATR) ChartKura Oncology Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Kura Oncology Inc. The current obv is 3,056,693.

Kura Oncology Inc Daily On-Balance Volume (OBV) ChartKura Oncology Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Kura Oncology Inc. The current mfi is 31.46.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Kura Oncology Inc Daily Money Flow Index (MFI) ChartKura Oncology Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Kura Oncology Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-25RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.

6.3. Candlestick Patterns

Kura Oncology Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Kura Oncology Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.188
Ma 20Greater thanMa 5020.211
Ma 50Greater thanMa 10020.801
Ma 100Greater thanMa 20017.539
OpenGreater thanClose17.860
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Kura Oncology Inc with someone you think should read this too:
  • Are you bullish or bearish on Kura Oncology Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Kura Oncology Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Kura Oncology Inc

I send you an email if I find something interesting about Kura Oncology Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Kura Oncology Inc.

Receive notifications about Kura Oncology Inc in your mailbox!